相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。ImmunoPET: Concept, Design, and Applications
Weijun Wei et al.
CHEMICAL REVIEWS (2020)
The cost of cancer in Europe 2018
Thomas Hofmarcher et al.
EUROPEAN JOURNAL OF CANCER (2020)
CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging
Gary A. Ulaner et al.
RADIOLOGY (2020)
Current Treatment Strategies for Multiple Myeloma
Andrew Branagan et al.
JCO ONCOLOGY PRACTICE (2020)
Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle
Imke H. Bartelink et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
Maddalena Centanni et al.
CLINICAL PHARMACOKINETICS (2019)
The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma
Leo Rasche et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Immuno-PET Imaging to Assess Target Engagement: Experience from 89Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors
C. Willemien Menke-van der Houven van Oordt et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
The beginning of the end for conventional RECIST - novel therapies require novel imaging approaches
Mirjam Gerwing et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study
Maria-Victoria Mateos et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Phase 1b trial of pembrolizumab monotherapy for relapsed/ refractory multiple myeloma: KEYNOTE-013
Vincent Ribrag et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Theranostic Outcomes in Clinical Practice of Oncology: What, So What, Now What? What's More
J. Harvey Turner
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2019)
What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model
Clement Bailly et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau et al.
LANCET (2019)
The future of checkpoint inhibition in multiple myeloma?
Caitlin Costello
LANCET HAEMATOLOGY (2019)
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
Maria-Victoria Mateos et al.
LANCET HAEMATOLOGY (2019)
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
Saad Zafar Usmani et al.
LANCET HAEMATOLOGY (2019)
Editorial: Immunotherapy in Multiple Myeloma
Nicola Giuliani et al.
FRONTIERS IN IMMUNOLOGY (2019)
Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture
Clement Bailly et al.
CANCERS (2019)
Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives
Alessandra Romano et al.
FRONTIERS IN ONCOLOGY (2019)
Biological Background of Resistance to Current Standards of Care in Multiple Myeloma
Pedro Mogollon et al.
CELLS (2019)
Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy
Sophia Danhof et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Challenges and shifting paradigms in clinical trials in oncology: the case for immunological and targeted therapies
Diana Carolina Sotelo-Rodriguez et al.
ECANCERMEDICALSCIENCE (2019)
Understanding Inter-Individual Variability in Monoclonal Antibody Disposition
Veena A. Thomas et al.
ANTIBODIES (2019)
Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry
Cecilie Hveding Blimark et al.
HAEMATOLOGICA (2018)
Preclinical Development of CD38-Targeted [89Zr] Zr-DFO-Daratumumab for Imaging Multiple Myeloma
Anchal Ghai et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Overcoming multiple myeloma drug resistance in the era of cancer 'omics'
Matthew Ho Zhi Guang et al.
LEUKEMIA & LYMPHOMA (2018)
Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry
Cecilie Hveding Blimark et al.
HAEMATOLOGICA (2018)
Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma
Enrico Caserta et al.
BLOOD (2018)
Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models
Sai Kiran Sharma et al.
CANCER RESEARCH (2018)
The Long Neglected Player: Modeling Tumor Uptake to Guide Optimal Dosing
Leire Ruiz-Cerda et al.
CLINICAL CANCER RESEARCH (2018)
Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis
Marjorie Pick et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Dealing with the spiralling price of medicines: issues and solutions
Chun K. K. Ma et al.
INTERNAL MEDICINE JOURNAL (2018)
89Zr-ImmunoPET companion diagnostics and their impact in clinical drug development
Brooke N. McKnight et al.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS (2018)
To all involved - we have a problem
[Anonymous]
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Functional Imaging Methods for Assessment of Minimal Residual Disease in Multiple Myeloma: Current Status and Novel ImmunoPET Based Methods
Neeta Pandit-Taskar
SEMINARS IN HEMATOLOGY (2018)
Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy
Elena Zamagni et al.
EXPERT REVIEW OF HEMATOLOGY (2018)
Comparison of Immuno-PET of CD138 and PET imaging with 64CuCl2 and 18F-FDG in a preclinical syngeneic model of multiple myeloma
Clément Bailly et al.
Oncotarget (2018)
Daratumumab for the Treatment of Multiple Myeloma
Torben Plesner et al.
FRONTIERS IN IMMUNOLOGY (2018)
Individualized Dosing of Therapeutic Monoclonal Antibodiesa Changing Treatment Paradigm?
Anne S. Strik et al.
AAPS JOURNAL (2018)
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
Niels W. C. J. van de Donk et al.
FRONTIERS IN IMMUNOLOGY (2018)
Checkpoint Inhibition in Myeloma: Opportunities and Challenges
Federica Costa et al.
FRONTIERS IN IMMUNOLOGY (2018)
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma
Xu Steven Xu et al.
ADVANCES IN THERAPY (2018)
Zr-89-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
Frederike Bensch et al.
NATURE MEDICINE (2018)
Immunotherapy Combinations in Multiple Myeloma - Known Unknowns
Nicole J. Gormley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer
A. N. Niemeijer et al.
NATURE COMMUNICATIONS (2018)
Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
Tomas Jelinek et al.
FRONTIERS IN IMMUNOLOGY (2018)
Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma
Stefania Oliva et al.
FRONTIERS IN IMMUNOLOGY (2018)
Immune Mediated Mechanisms of Resistance to Daratumumab
Domenico Viola et al.
BLOOD (2018)
CD38 antibodies in multiple myeloma: back to the future
Niels W. C. J. van de Donk et al.
BLOOD (2018)
Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis
Kayode Ogungbenro et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?
Jacalyn Rosenblatt et al.
BLOOD (2017)
Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment
Pamela L. Clemens et al.
CLINICAL PHARMACOKINETICS (2017)
End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma
Antje Hoering et al.
FUTURE ONCOLOGY (2017)
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group
Michele Cavo et al.
LANCET ONCOLOGY (2017)
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Mizuki Nishino et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
L. Rasche et al.
NATURE COMMUNICATIONS (2017)
MRD in multiple myeloma: more questions than answers?
Philippe Moreau et al.
BLOOD CANCER JOURNAL (2017)
Radioimmunotherapy for non-Hodgkin's lymphoma; positioning, safety, and efficacy of 90Y-Ibritumomab. 10 years of experience and follow-up
A. Martinez et al.
REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR (2017)
Radioimmunotherapy of lymphoma: an underestimated therapy optionRadioimmunotherapy of lymphoma: an underestimated therapy option
Karin Hohloch
LANCET HAEMATOLOGY (2017)
Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With NewCancer Medicines
Sebastian Salas-Vega et al.
JAMA ONCOLOGY (2017)
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Jakub Krejcik et al.
CLINICAL CANCER RESEARCH (2017)
Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma
X. S. Xu et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Whither Radioimmunotherapy: To Be or Not To Be?
Damian J. Green et al.
CANCER RESEARCH (2017)
Immuno-PET for Clinical Theranostic Approaches
Clement Bailly et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors
M. Ahamadi et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors
G. Bajaj et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives
S. Lonial et al.
LEUKEMIA (2016)
Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab
Salma Afifi et al.
ANNALS OF PHARMACOTHERAPY (2016)
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
Andrzej Jakubowiak et al.
BLOOD (2016)
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
Inger S. Nijhof et al.
BLOOD (2016)
ImmunoPET to help stratify patients for targeted therapies and to improve drug development
Francoise Kraeber-Bodere et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
Alexander M. Lesokhin et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
T cells in multiple myeloma display features of exhaustion and senescence at the tumor site
Claudia Zelle-Rieser et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Multiple myeloma epidemiology and survival: A unique malignancy
Dickran Kazandjian
SEMINARS IN ONCOLOGY (2016)
Approaches to modernize the combination drug development paradigm
Daphne Day et al.
GENOME MEDICINE (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease
J. Paton-Hough et al.
BONE (2015)
Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab
Kristoff Muylle et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
B. Paiva et al.
LEUKEMIA (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Generation and Characterization of Microvesicles after Daratumumab Interaction with Myeloma Cells
Antonella Chillemi et al.
BLOOD (2015)
Single-dose anti-cd138 radioimmunotherapy: bismuth-213 is more efficient than lutetium-177 for treatment of multiple myeloma in a preclinical model
Nolwenn Fichou et al.
FRONTIERS IN MEDICINE (2015)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies
Antoine Deslandes
MABS (2014)
Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy
S. Gouard et al.
NUCLEAR MEDICINE AND BIOLOGY (2014)
Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies
Miroslav Dostalek et al.
CLINICAL PHARMACOKINETICS (2013)
90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial
Christian W. Scholz et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
213Bi Radioimmunotherapy with an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma
Michel Cherel et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma
H. Tamura et al.
LEUKEMIA (2013)
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
Jeffrey A. Zonder et al.
BLOOD (2012)
Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET
Saiyada N. F. Rizvi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?
Rong Deng et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
Monoclonal antibody dose determination and biodistribution into solid tumors
Robert A. Beckman et al.
THERAPEUTIC DELIVERY (2011)
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Ron J. Keizer et al.
CLINICAL PHARMACOKINETICS (2010)
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
E. C. Dijkers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Radioimmunotherapy of Lymphoma: A Treatment Approach Ahead of Its Time or Past Its Sell-By Date?
Tim Martin Illidge
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cancer Therapy with Alpha-Emitters Labeled Peptides
Ekaterina Dadachova
SEMINARS IN NUCLEAR MEDICINE (2010)
Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma
Franck Morschhauser et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Syndecan-1: a dynamic regulator of the myeloma microenvironment
Ralph D. Sanderson et al.
CLINICAL & EXPERIMENTAL METASTASIS (2008)
Immuno-PET: A navigator in monoclonal antibody development and applications
Guus A. M. S. van Dongen et al.
ONCOLOGIST (2007)
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
分享论文
